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Novelty & Impact Statement  
Telomerase (TERT) is ubiquitously activated in cancer through complex relatively 
unknown mechanisms.  In the TERT dependent bladder cancer, we uncover that 
hypermetylation of the TERT promoter (THOR) is a dynamic and progressive 
process during carcinogenesis and when combined with early TERT promoter 
mutations THOR affects disease progression and patient outcome. The collaborative 
effects of genetic and epigenetic alterations on TERT and tumor recurrence provide 
new insights into telomere biology and may be applicable to other tumor types.  
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Telomerase reverse transcriptase (TERT) activation is central to cancer cell 
immortalization. It acts, however, through relatively unknown mechanisms. In 
urothelial bladder cancer (UBC) in particular, TERT activation can occur in the 
presence or absence of mutation, raising questions about alternative activation 
mechanisms. This study shows that hypermethylation of the TERT promoter (THOR) 
plays a key part in UBC, being a dynamic and progressive process, with 
hypermethylation levels increasing with bladder cancer severity. Moreover, both 
hypermethylation and TERT promoter mutation contributed to increased telomerase 
expression. The findings provide insight into telomere biology in UBC and may be 
applicable to other tumors. 
 
Abstract 
In urothelial bladder cancer (UBC), risk stratification remains an important 
unmet need. Limitless self-renewal, governed by TERT expression and 
telomerase  activation, is crucial for cancer progression. Thus, telomerase 
activation through the interplay of mutations (TERTpMut) and epigenetic 
alterations in the TERT promoter may provide further insight into UBC 
behavior. Here, we investigated the combined effect of TERTpMut and the 
TERT Hypermethylated Oncological Region (THOR) status on telomerase 
activation and patient outcome in a UBC international cohort (n=237). We 
verified that TERTpMut were frequent (76.8%) and present in all stages and 
grades of UBC. Hypermethylation of THOR was associated with higher TERT 
expression and higher-risk disease in non-muscle invasive bladder cancers 
(NMIBC). TERTpMut alone predicted disease recurrence (HR: 3.18, 95%CI 
1.84 to 5.51, p<0.0001) but not progression in NMIBC. Combined 
THORhigh/TERTpMut increased the risk of disease recurrence (HR 5.12, 
p<0.0001) and progression (HR 3.92, p=0.025). Increased THOR 
hypermethylation doubled the risk of stage progression of both TERTpwt and 
TERTpMut NMIBC. These results highlight that both mechanisms are common 
and coexist in bladder cancer and while TERTpMut is an early event in 
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bladder carcinogenesis THOR hypermethylation is a dynamic process that 
contributes to disease progression. While the absence of alterations 
comprises an extremely indolent phenotype, the combined genetic and 
epigenetic alterations of TERT bring additional prognostic value in NMIBC and 
provide a novel insight into telomere biology in cancer.  
 
 
 
Introduction  
Urothelial bladder cancer (UBC) poses significant burden as it is responsible 
for 123,051 deaths annually and at any given time there are more 
than 500,000 UBC patients in the USA alone (1, 2). UBC is a remarkably 
heterogeneous disease, including non-muscle invasive (NMIBC) and muscle 
invasive disease (MIBC). Pathological tumor stage and grade drive prognostic 
predictions and ultimately, therapy recommendations. However, pathology 
alone is often insufficient to predict individual outcomes.  Grade and stage are 
crude measures and many patients are over- or undertreated as a result. 
Unlike other cancer types, few molecular markers currently guide UBC 
management (3, 4).  
 
At diagnosis the majority of UBC (75%) are NMIBC (Ta, T1), mostly low grade 
(LG).  LG tumors are rarely lethal but recur locally with variable and 
unpredictable rates (5, 6). Muscle-invasive bladder cancers (MIBC – T2, T3, 
T4), on the other hand, almost universally high-grade (HG), can be lethal and 
associated with worse clinical outcomes (5, 6). A subset of NMIBC are HG 
and destined to progress to life-threatening MIBC. There is an unmet need to 
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improve the prediction of those patients with NMIBC at risk of progression to 
MIBC. The stakes are high as NMIBC can be managed with conservative 
therapy whereas MIBC requires either the removal of the bladder 
(cystectomy) or chemo-radiation (7). 
  
Telomerase, the enzyme complex responsible for maintaining telomere length 
and genome integrity is responsible for cellular immortalization (a hallmark of 
cancer) (8-11). Telomerase activity is upregulated in 85-90% of all cancers 
(12, 13). Mutations in the promoter of the catalytic subunit of the enzyme, 
termed telomerase reverse transcriptase (TERT) are frequently observed in 
several cancers and drive telomere maintenance (14-16). In UBC, TERT 
promoter mutations (C to T transitions at chr5:1,295,228 and chr5:1,295,250) 
are more common than any other genetic alterations and can lead to 
increased TERT expression and telomerase activity (17-20). Importantly, 
TERT promoter mutations are associated with worse clinical outcome in most 
studies further highlighting the role of telomerase activation in tumor 
progression and recurrence (18-27). Noteworthy, not all TERTpMut tumors 
display telomerase activation and non-TERTpMut UBC may express TERT 
suggesting that the presence of additional mechanisms are necessary for 
telomerase activation in UBC (28). 
 
Our group and others have identified a parallel epigenetic control of 
telomerase activation in cancer. Specifically, a region located upstream of the 
core mutation area, within the TERT promoter, termed THOR (TERT 
Hypermethylated Oncological Region) is hypermethylated in many TERT-
expressing cancers, is associated with telomerase activation and predicts 
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clinical outcomes in multiple tumor types (14, 29, 30). We therefore 
hypothesized that dual mechanisms activate telomerase in UBC. Here, we 
studied the interaction and contribution of both genetic (TERTpMut) and 
epigenetic (THOR) TERT promoter alterations to telomerase activation and 
prognosis in UBC, using a multi-institutional cohort. 
 
 
 
 
Material and Methods  
Open Access Data  
The Cancer Genome Atlas (TCGA) Research Network 
(http://cancergenome.nih.gov) database for UBC was analyzed. A single, 
probe located within THOR (cg11625005) was used for methylation analysis 
(Illumina Infinium 450k array). TERT expression data were evaluated from the 
gene expression dataset (polyA+IlluminaHiSeq) (details in Appendix).  
 
Patients 
Patients’ selection and pathological characteristics are presented in 
Supplementary Table S1. All patients underwent surgery (either transurethral 
bladder resection or radical cystectomy) and followed for a median period of 
107.4 months (IQR: 32.4–266.8 months). 331 bladder tissue samples, from 
331 patients (237 UBC and 94 normal urothelium) were collected and 
analyzed for THOR methylation, TERT promoter mutations and a subgroup 
for hTERT expression. Survival data was collected for the 237 patients with 
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UBC. On 10 of these patients, an additional tumor at recurrence/progression 
was analyzed. 
 
Molecular analysis of the TERT promoter 
Sanger Sequencing was used to determined TERT promoter mutation status. 
Samples were considered mutant (TERTpMut) if any of the mutations 
(1,295,228 G>A or 1,295,250 G>A) were present (Supplementary Table S2). 
Quantitative sodium bisulfite pyrosequencing was performed for THOR as 
previously described (30). TERT expression was performed with the QX200 
Droplet Digital PCR system (see Appendix for details).  
 
Statistical analysis 
SAS version 9.4 was used for statistical analyses. THOR was initially 
evaluated as a continuous value to determine its association with normal and 
malignant urothelial bladder tissue and to further interrogate its association 
with stage, grade and high and low risk disease. For the prognostic model we 
dichotomized into high- and low-THOR-methylation groups by receiver 
operating characteristic (ROC) analysis. Clinical outcomes for the TERT 
promoter mutations and THOR methylation were determined by Kaplan-Meier 
Survival curves. Cox Proportional Hazards (CPH) models were used to 
assess univariate and multivariate significance (details Appendix).  
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Results 
TERT promoter mutations are early and frequent events in UBC  
TERT promoter mutations (TERTpMut) were highly prevalent (76.8%, n=182). 
The predominant alteration was g.1,295,228 C>T which accounted for 90.1% 
of all mutations. No mutations were found in normal urothelium (Table 1). 
 
TERTpMut were identified in all stages and grades of UBC [detected in 69.3% 
of NMIBC (n=135/199) and 73.4% of low-grade lesions]. TERTpMut were 
identified in all metastatic (tumor positive) pelvic lymph nodes as well as in 
their corresponding primary tumor. Interestingly, TERTpMut were also identified 
in some tumor negative lymph nodes (Supplementary Table S3). 
 
Consistent with previous studies, some of these TERTpMut UBC did not exhibit 
high TERT expression even when compared to UBC with a wild type promoter 
(TERTpWt) (Supplementary Fig.S1A, S1C) (18). 
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These data support an early oncogenic role of TERTpMut and the possibility 
that other mechanisms may also upregulate TERT expression in UBC. 
 
THOR hypermethylation is a dynamic process in UBC tumorigenesis  
In order to evaluate the extent of THOR methylation and its effect on TERT 
expression in UBC we analyzed a representative CG site within THOR 
(cg11625005) in a cohort of MIBC from the TCGA (n=433). When compared 
to normal urothelium, MIBC had significantly higher methylation at THOR and 
higher TERT mRNA levels (Supplementary Fig.S2A, p<0.0001; 
Supplementary Fig.S2B, p<0.0001). THOR hypermethylated (THORhigh) was 
associated with considerably higher TERT mRNA levels in malignant tissue 
(Supplementary Fig.S2C, p<0.0001) further supporting the role of TERT 
promoter methylation in TERT transcriptional activation.   
 
To directly test this observation we assayed multiple representative CG sites 
from THOR in normal and UBC samples from our multi-institutional cohort. 
THOR was hypermethylated (THORhigh) in 127 UBC (53.6%, Table 1) and 
significantly hypermethylated in tumors compared to benign histology in non-
matched samples (Figure 1A, p<0.0001). Additionally, paired samples from 
the same surgical specimen revealed that THOR methylation is 2 times higher 
in the tumor region than the corresponding normal urothelium (Figure 1B).  
 
Since UBC are stratified by invasiveness (T stage) and cellular morphology 
(grade) as predictors of tumor progression, we also tested THOR ability to 
distinguish stages and grades. THOR methylation was significantly higher in 
tumor tissue, even when comparing superficial lesions (Ta) with normal tissue 
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(Figure 1C, p<0.0001). THOR methylation levels are slightly higher in T1 
disease than in Ta (Figure 1C, p=0.049) but do not reach the same significant 
difference verified between normal urothelium and Ta disease. Similarly, 
THOR methylation demonstrated a progressive pattern from normal 
urothelium to low-grade tumors and maintaining the same trend in high-grade 
tumors (Figure 1D). Clinically, THOR exhibited higher hypermethylation in 
high-risk (T1 and HG) when compared to low risk tumors (Supplementary 
Fig.S3, p=0.034)(31). 
 
To further explore the changes in THOR over time, we assessed THOR 
methylation in UBC harvested from consecutive surgeries (at both the time of 
the initial diagnosis and the first recurrence or progression). A significant 
increase in THOR methylation levels was observed in tumors with stage 
progression (p=0.018, mean increase fold of 1.76), but not in non-progressive 
ones (p=0.88) suggesting that THOR is hypermethylated in tumors harboring 
TERT promoter mutations (Supplementary Table S4). 
 
Finally, analysis of TERT expression revealed that higher levels of THOR 
methylation are related to higher levels of expression (Supplementary 
Fig.S1B, p=0.049).  The highest TERT expression is observed when both 
alterations (methylation and mutations) are present (Supplementary Fig.S1C). 
 
Overall, these data suggest that THOR methylation increases progressively 
during the earlier stages of UBC and both TERT promoter mutations and 
hypermethylation contribute to increased telomerase expression.  
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Prognostic value of TERT promoter alterations in NMIBC 
As expected, in these selected cohorts, pathological grade was predictive of 
progression (n=199, p=0.02) (Supplementary Fig.S4).  
 
As THOR methylation increases with disease stage while TERTpMut is an early 
event, we assessed the value of TERT promoter alterations as markers of 
recurrence and disease progression in NMIBC.  
 
Consistent with previous reports, patients harboring TERTpMut had a 
significantly higher risk of recurrence (HR: 3.18, 95% CI 1.8-5.5; p<0.0001; 
Table 2) with significantly decreased median disease free survival (Log rank 
p<0.0001; Figure 2A)(17, 18, 25). However, TERTpMut status did not reach 
statistical significance with respect to the risk of progression to invasive 
disease (p=0.052) (Figure 2B, Table 2)(17, 18). 
 
As for TERTpMut, THORhigh NMIBC recurred more frequently (HR: 1.5, 95% CI 
1.02-2.20; p=0.03; Table 2), with decreased median disease-free survival (76 
months vs. 31.7 months) (Log rank p=0.034; Figure 2C). Also, THORhigh did 
not reach significance for the risk of progression (Log rank p=0.059; Figure 
2D, Table 2) in NMIBC.   
 
Combined TERT promoter alterations predict disease progression in 
NMIBC  
We then analyzed the combined prognostic impact of both TERT promoter 
alterations in NMIBC. We first evaluated the association of TERT promoter 
alterations and clinical outcomes according to grade and stage of NMIBC. 
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THORhigh/TERTp
Mut was the most common phenotype in NMIBC which 
recurred or progressed independently of stage (Supplementary Fig.S5 and 
S6). The absence of any alteration  (THORlow/TERTp
Wt) was associated with a 
more indolent phenotype even in HG NMIBC (Supplementary Fig.S6).  
 
Concomitant THOR hypermethylation and mutations (THORhigh/TERTp
Mut) 
were associated with increased risk of disease recurrence (HR: 5.12; 95% CI 
2.23-11.32, Table 2) with less than 30% disease free survival (DFS) at 10 
years. In contrast, the absence of both alterations (THORlow/TERTp
Wt) was 
associated with 80% DFS at 10 years (Figure 3A, Log rank p<0.0001).  The 
presence of either TERT promoter alterations (TERTpMut or THORhigh) 
increased the risk of disease recurrence with a worse disease free survival 
(30.8% and 45% at 10 years, respectively; Figure 3A).  
 
The presence of either TERT promoter alterations conferred a 4.53 fold 
increased risk of recurrence (95% CI 2.05-10.01; p=0.0002) but not for 
progression (p=0.14). Combined THORhigh /TERTp
Mut was a risk factor for both 
recurrence (HR: 5.4; CI 95% 2.42-12.04; p<0.0001) and progression (HR: 
4.01; CI 95% 1.19-13.5; p=0.024;Table 2). Furthermore, THORlow/TERTp
Wt 
NMIBC patients had a 91.4% progression free survival (PFS) at 10 years of 
follow-up, significantly better than THORhigh/TERTp
Mut (66.4% PFS; Log rank 
p=0.019; Figure 3B). When adjusting for stage (T1 vs. Ta), grade (HG vs LG), 
gender and age, THORhigh/TERTp
Mut also displays a trend towards 
significance (HR: 3.32, CI 95% 0.99-11.16; p=0.05) (Supplementary Table 5).  
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We then tested the effect of continuous increase in THOR methylation to 
enhance the predictive ability of disease progression in NMIBC, adjusting for 
TERT promoter mutations status. THOR levels affected disease progression 
in both TERTpMut and TERTpWt phenotypes. Increased THOR methylation 
from 10% (normal) to 50%, more than doubled the risk of disease progression 
independently of TERT promoter mutation status (Figure 4). 
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Discussion  
This study is the first to assess concomitant TERT promoter alterations in 
UBC. Our results suggest a temporal and cooperative association between 
TERT promoter mutations and methylation, impacting telomere biology and 
clinical outcome.  
   
TERT expression is upregulated in 85-90% of tumors via multiple molecular 
mechanisms including somatic mutations, TERT amplifications, TERT 
structural variants and epigenetic modifications through TERT promoter 
methylation (14). Our data reveal that 76.8% of UBC cancers harbor 
TERTpMut and 53.6% have THORhigh,  and 24.6% (n=49/199) of LG NMIBC 
acquired both alterations . The kinetics and interaction of these alterations in 
UBC, and the resulting effect on TERT expression are still unknown and 
important to decipher. 
 
The observation that TERTpMut are found ubiquitously across all stages and 
grades of UBC, even in low stage and grade lesions with low TERT 
expression, suggests that TERTpMut is an early event necessary but 
insufficient by itself to drive disease progression. In fact other studies also 
verified that TERT promoter mutant UBC might express low mRNA levels 
(18). Similar data exist in other tumors where TERT promoter mutations are 
common.  For example, in gliomas, TERTpMut are detected in lower grade 
lesions where TERT expression and self-renewal are low (32,33). 
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TERTpMut is necessary but not sufficient to maintain telomere length or 
telomerase upregulation (28). In TERTpMut  tumors additional alterations are 
likely required to upregulate telomerase and promote tumor progression.  
 
We previously showed that THOR hypermethylation is a dynamic process 
during gliomagenesis and prostate cancer progression (29, 30). In UBC, 
TERTpMut is an early event while THOR hypermethylation is associated with 
disease progression and increased TERT expression.  This pattern has been 
observed in other cancer types (14, 29, 30). 
 
A weakness of the WHO 2004/2016 pathological classification of NMIBC is 
that it gives almost no prognostic information in T1 patients as nearly all are 
classified as HG (34). In this study, TERT promoter alterations add significant 
value as prognostic biomarkers.  For example, T1 THORlow/TERTpWt tumors, 
including HG lesions, carry a risk of progression of less than 10%, in sharp 
contrast with the 52% of progression for THORhigh/TERTpMut. If confirmed in 
prospective studies, this may help guide management when choosing 
conservative vs. aggressive therapy for these patients. Given the high 
recurrence rate in NMIBC, the identification of patients with very low potential 
for disease recurrence and progression might change the costly and invasive 
follow-up protocols in favor of individualized strategies. 
 
In contrast, THORhigh/TERTpMut significantly increased the chance of NMIBC 
recurrence and is a risk factor for disease progression across stages and 
grades. Furthermore, for the different TERT promoter mutation status, 
continuous THOR hypermethylation increases the risk of disease progression, 
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reinforcing the dynamic and crucial role of THOR methylation in bladder 
cancer tumorigenesis.Further supporting the role of THOR methylation, 
tumors exhibited higher THOR methylation at the time of stage progression.  
 
Together, our findings support the hypothesis that TERTpMut are early triggers 
in tumorigenesis which require cooperation with other events including THOR 
hypermethylation to ensure telomerase activation, immortality and disease 
progression.  
 
The exact mechanism of telomerase activation by promoter hypermethylation 
is still under investigation. One possible explanation is that methylation leads 
to three-dimensional changes in local chromatin architecture resulting in 
increased transcription (35). Alternatively, methylation of this distal part of the 
promoter might also prevent the binding of transcriptional repressors, which in 
turn enables TERT expression (36). These mechanisms ought to be explored 
further as they may result in the development of novel targeted therapies. 
Demethylating agents have shown some encouraging results in cancers 
where THOR is hypermethylated, and may have a role in decreasing the risk 
of progression of NMIBC (37). 
 
Our study has limitations due to its retrospective nature, patient selection, 
absence of centralized pathology review (although we chose specifically the 
HG vs LG 2004/16 WHO classification less prone to inter-observer variability) 
(34). Importantly, one should interpret the univariate and multivariate analysis 
with caution as Ta ant T1 tumors are treated differently. Furthermore, since 
large numbers of tumors are necessary for survival analysis in NMIBC, in our 
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multivariate analysis THORHigh/TERTpMut only showed a trend towards 
significance as a risk factor for disease progression. Future studies with 
higher number of NMIBC tumors are needed to empower and statically 
validate our preliminary findings.  Similarly, the limited numbers of patients 
with muscle invasive disease prevented a meaningful evaluation of this 
subgroup. However, since most of the prognostic role of TERT activation 
through THOR hypermethylation is observed during early stages of tumor 
development in multiple cancers, and NMIBC was the focus of the present 
study, our results suggest a similar process in UBC carcinogenesis 
 
In summary, this study further supports the role of epigenetic control of the 
TERT promoter by THOR hypermethylation as a dynamic and progressive 
process in carcinogenesis, including UBC. The concomitant evaluation of 
TERT promoter mutation-methylation in NMIBC has identified a group with 
more indolent outcome, independently from grade or stage. Additional 
prospective studies should confirm that THORlow/TERTpWt tumors have a 
reduced risk of recurrence and progression to invasive disease. This should 
be explored in other tumor types known for harboring TERT promoter 
mutations and telomerase upregulation. A better understanding of the 
interplay between these two tumor-specific TERT activating mechanisms 
might improve clinical management in UBC and other TERT-dependent 
cancers. 
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Figure Legends.  
 
Figure 1. THOR methylation in urothelial bladder cancer.  
A) THOR methylation status in normal urothelium and tumor tissue in the 
entire cohort (****, p<0.0001) B) The ratio of tumor/normal tissue in paired 
samples from the same patient (n=38). Note a mean of 2 fold increase in 
THOR methylation status in the malignant tissue. C) THOR methylation status 
in different tumor stages. D) THOR methylation status is within tumor grades, 
but low grade has significantly higher THOR methylation than normal 
urothelilum (****, p<0.0001). NS=non significant. Error bars represent median 
and Interquartile range (IQR).  
 
 
Figure 2. Survival estimates for patients with NMIBC stratified by TERT 
promoter alterations.  
A) Disease free and B) progression free survival for patients with NMIBC 
stratified by TERT promoter mutation status. C) Disease free and D) 
progression free survival for patients with NMIBC stratified by TERT promoter 
methylation status.  THORlow=THOR hypomethylated, THORhigh=THOR 
hypermethylated. TERTpWt=TERT promoter wild type (for the two studied 
mutations); TERTpMut = TERT promoter mutant.  Yellow =TERTpWt and 
THORlow; Blue= TERTpMut and THORhigh 
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Figure 3. Survival analysis of combined TERT promoter alterations in 
patients with NMIBC. Kaplan-Meier analysis for A) disease free and B) 
progression free survival stratified by combined TERT promoter mutations 
and THOR methylation status in non-muscle invasive bladder cancer patients.  
THORlow/TERTpWt = blue; THORlow/TERTpMut=light red;THORhigh/TERTpWt  
=green; THORhigh/TERTpMut=dark red.  
 
Figure 4. Estimated probability of disease progression based on THOR 
methylation levels. Risk of progression is estimated by any TERT promoter 
mutation status (wild type or mutant) as a result of increased THOR 
methylation. Red-TERT promoter mutant NMIBC, Black- TERTpWt NMIBC. 
 
 
Table 1. Summary of TERT promoter methylation (THOR) and TERT 
promoter mutation status. 
 
THOR Methylation  
THOR
low
 110 46.4%  
THOR
high
 127 53.6% 
Stage THOR
low
 THOR
high
 
Ta 45 43.7% 58 56.3% 
T1 49 51% 47 49% 
≥ T2 16 42.1% 22 57.9% 
Total  110 46.4% 127 53.6% 
Grade THOR
low
 THOR
high
 
Low Grade   76  56.3%  59  43.5% 
High Grade   28  27.5%  74  72.5% 
Total  104  43.9% 133  56.1% 
TERT promoter mutations  
TERTp
MutStatus
  
TERTp
Wt 
 55 23.2% 
TERTp
Mut
 182 76.8% 
 TERT promoter mutations (per mutation)  
C228T 164 90.1% 
C250T 18  9.9% 
C228T/C250T 0 0% 
Total 182 100% 
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Stage Wt (n/%) Mutant (n/%) 
Ta 28 27.2% 75 72.8% 
T1 23 24.0% 73 76.0% 
≥ T2 4 10.5% 34 89.5% 
Total  55  23.2% 182  76.8% 
Grade Wt (n/%) Mutant (n/%) 
Low Grade  36 26.7% 99 73.4% 
High Grade  19 18.6% 83 81.4% 
Total  55  23.2% 182  76.8% 
THOR
low
 =THOR hypomethylated; THOR
high 
= THOR hypermethylated;TERTp
MutStatus 
 =TERT promoter mutation 
status; TERTp
Mut 
= TERT promoter mutation; TERTp
Wt  
=TERT promoter wild type. 
Frequency of TERT promoter mutations  (wild type and mutant) and THOR methylation (hypomethylated and 
hypermethylated) according to stage and grade disease.  
 
 
 
 
Table 2. Univariate Cox proportional hazards regression analysis of time 
for disease recurrence and disease progression in NMIBC (n=199).  
 
 
Disease Recurrence Disease Progression 
HR 95% CI Chi Sq P HR 95% CI Chi Sq P 
TERTp
MutationStatus
 
 
TERTp
Wt  
(n=51) Ref Ref 
TERTp
Mut 
(n=148) 3.18 1.8 to 5.5 17.16 <0.0001 2.36 0.99 to 5.60 3.82 0.052 
THOR
Methy 
 
THOR
low 
(n=105) Ref Ref 
THOR
high 
(n=94) 1.50 1.0 to 2.2 4.37 0.03 1.81 0.97 to 3.35 3.52 0.057 
THOR
Methy
/TERTp
MutStatus 
THOR
low
/TERTp
Wild
 
(n=35) 
Ref Ref 
THOR
low
/TERTp
Mut 
+ 
THOR
high
/TERTp
Wild 
(n=85) 
4.53  2.0 to 10  13.86 0.0002  2.64  0.77 to 9.1  2.38  0.123  
THOR
high
/TERTp
Mut 
(n=79) 
5.12 2.3 to 11.3 16.33 <.0001 3.92 1.2 to 13.0 4.97 0.025 
HR=Hazard ratio; CI: confidence interval; Chi Sq= Chi Squared  
TERTp
MutStatus 
=TERT promoter mutation status (for the studied mutations); TERTp
Wt
=TERT promoter 
wild type; TERTp
Mut
 = TERT promoter mutant; THOR
Methy
 = THOR methylation status; THOR
high
=THOR 
hypermethylated; THOR
low
=THOR hypomethylated 
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